Daiichi Sankyo Austria

Address: Effingergasse 21, 1160 Vienna,Austria

Tel: +43 1 48586420

Web: http://www.daiichi-sankyo.at/

Company description

Daiichi Sankyo Austria GmbH is the Austrian affiliate of Daiichi Sankyo, a global pharmaceutical company that focuses on researching and marketing innovative medications. The company’s roots extend back to 1899 and the early days of industrialization of the pharmaceutical sector.
The company itself was created in 2005 through the merger of two traditional Japanese enterprises, Daiichi and Sankyo. With net sales of nearly €8.6 billion in fiscal year 2011, Daiichi Sankyo is one of the world’s 20 leading pharmaceutical companies. The company does business in nearly 60 countries around the world. Daiichi Sankyo’s world headquarters are in Tokyo, Japan.
The company’s roots in Europe extend back to the 1980s, when both Daiichi and Sankyo established offices in Düsseldorf, Germany. The company currently does business in 12 European countries including Austria. With nearly 2,500 employees, Daiichi Sankyo has been one of the strongest Japanese pharmaceutical companies located in Europe.
Striving for innovation is a central task of Daiichi Sankyo. Innovation is the fundamental requirement for achieving the corporate goal of developing pharmaceutical products that are the best in their class or for establishing a new class of active ingredients. Furthermore, the commitment to fulfill or exceed the high expectations of stakeholders regarding corporate services, information and organizational processes is based on innovation as a fundamental principle.

Products and services

The Daiichi Sankyo Group is dedicated to the creation and supply of innovative pharmaceutical products to address the diversified unmet medical needs of doctors and patients. In its research, the company aims to develop drugs that are either “Best-in-Class” or create a new class of therapeutic solutions.
While maintaining its portfolio of marketed pharmaceuticals for hypertension, hyperlipidemia, and bacterial infections, Daiichi Sankyo is engaged in the development of treatments for patients with thrombotic disorders and is focused on the discovery of novel oncology and cardiovascular-metabolic therapies.egulations. Detailed information about such drugs, such as the performance of our products may be provided only to medical professionals. For this reason, we can only give you an overview of our main products.